← Back to Screener
Gossamer Bio, Inc. Common Stock (GOSS)
Price$0.42
Favorite Metrics
Price vs S&P 500 (26W)-89.68%
Price vs S&P 500 (4W)4.40%
Market Capitalization$98.57M
All Metrics
Book Value / Share (Quarterly)$0.13
P/TBV (Annual)14.41x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.73
Price vs S&P 500 (YTD)-90.38%
Net Profit Margin (TTM)-351.49%
EPS (TTM)$-0.74
10-Day Avg Trading Volume7.15M
EPS Excl Extra (TTM)$-0.74
EPS (Annual)$-0.75
ROI (Annual)-24.90%
Cash / Share (Quarterly)$0.59
Revenue Growth QoQ (YoY)47.13%
ROA (Last FY)-98.91%
EBITD / Share (TTM)$-0.71
ROE (5Y Avg)-528.46%
Operating Margin (TTM)-352.23%
Cash Flow / Share (Annual)$-0.73
P/B Ratio3.40x
P/B Ratio (Quarterly)7.07x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)5.35x
Net Interest Coverage (TTM)-17.90x
ROA (TTM)-75.50%
EPS Incl Extra (Annual)$-0.75
Current Ratio (Annual)2.64x
Quick Ratio (Quarterly)2.35x
3-Month Avg Trading Volume12.67M
52-Week Price Return-50.15%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.46
P/S Ratio (Annual)2.03x
Asset Turnover (Annual)0.28x
52-Week High$3.87
EPS Excl Extra (Annual)$-0.75
CapEx CAGR (5Y)-44.50%
26-Week Price Return-82.79%
Quick Ratio (Annual)2.35x
13-Week Price Return-82.86%
Total Debt / Equity (Annual)6.70x
Current Ratio (Quarterly)2.64x
Enterprise Value$259.348
Asset Turnover (TTM)0.21x
Book Value / Share Growth (5Y)-53.08%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-351.67%
Cash / Share (Annual)$0.59
3-Month Return Std Dev188.97%
Net Income / Employee (TTM)$-1
ROE (Last FY)-191.67%
Net Interest Coverage (Annual)-17.90x
EPS Basic Excl Extra (Annual)$-0.75
Receivables Turnover (TTM)5.52x
Total Debt / Equity (Quarterly)6.83x
EPS Incl Extra (TTM)$-0.74
ROI (TTM)-23.00%
P/S Ratio (TTM)2.03x
Revenue / Share (Annual)$0.21
Tangible BV / Share (Annual)$0.13
Price vs S&P 500 (52W)-84.78%
Year-to-Date Return-86.45%
5-Day Price Return-2.69%
EPS Normalized (Annual)$-0.75
ROA (5Y Avg)-65.35%
Net Profit Margin (Annual)-351.49%
Month-to-Date Return27.85%
Cash Flow / Share (TTM)$-1.55
EBITD / Share (Annual)$-0.71
Operating Margin (Annual)-352.23%
LT Debt / Equity (Annual)6.70x
ROI (5Y Avg)-63.48%
LT Debt / Equity (Quarterly)6.81x
EPS Basic Excl Extra (TTM)$-0.74
P/TBV (Quarterly)1.66x
P/B Ratio (Annual)6.95x
Pretax Margin (TTM)-351.67%
Book Value / Share (Annual)$0.13
Price vs S&P 500 (13W)-85.24%
Beta2.30x
P/FCF (Annual)4928.62x
Revenue / Share (TTM)$0.21
ROE (TTM)-118.77%
52-Week Low$0.32
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.20
4.19
3.73
3.75
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
GOSSGossamer Bio, Inc. Common Stock | 2.03x | — | — | — | $0.42 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Gossamer Bio is a clinical-stage biopharmaceutical company developing therapeutics in immunology, inflammation, and oncology. Its pipeline includes Seralutinib for pulmonary arterial hypertension, GB004 for inflammatory bowel disease, GB1275 for oncology indications, and GB001 for eosinophilic asthma.